BTIG Reiterates Buy Rating on Cullinan Therapeutics, Keeps $40 Target
BTIG reiterated its Buy rating and $40 price target on Cullinan Therapeutics. The target implies 209.4% upside from the stock’s Oct. 16 close of $12.93.
BTIG reiterated its Buy rating and $40 price target on Cullinan Therapeutics. The target implies 209.4% upside from the stock’s Oct. 16 close of $12.93.